These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21931802)

  • 1. Involvement of mTOR in CXCL12 mediated T cell signaling and migration.
    Munk R; Ghosh P; Ghosh MC; Saito T; Xu M; Carter A; Indig F; Taub DD; Longo DL
    PLoS One; 2011; 6(9):e24667. PubMed ID: 21931802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
    Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH
    J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
    Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
    Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
    Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
    Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis.
    Dillenburg-Pilla P; Patel V; Mikelis CM; Zárate-Bladés CR; Doçi CL; Amornphimoltham P; Wang Z; Martin D; Leelahavanichkul K; Dorsam RT; Masedunskas A; Weigert R; Molinolo AA; Gutkind JS
    FASEB J; 2015 Mar; 29(3):1056-68. PubMed ID: 25466898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
    Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
    Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer.
    Guo JC; Li J; Zhou L; Yang JY; Zhang ZG; Liang ZY; Zhou WX; You L; Zhang TP; Zhao YP
    Oncotarget; 2016 Sep; 7(38):62006-62018. PubMed ID: 27542220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration.
    Ghosh MC; Collins GD; Vandanmagsar B; Patel K; Brill M; Carter A; Lustig A; Becker KG; Wood WW; Emeche CD; French AD; O'Connell MP; Xu M; Weeraratna AT; Taub DD
    Blood; 2009 Aug; 114(7):1366-73. PubMed ID: 19520808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR.
    Rosner M; Hengstschläger M
    Oncogene; 2011 Nov; 30(44):4509-22. PubMed ID: 21602892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12-induced T lymphocyte migration.
    Varrin-Doyer M; Vincent P; Cavagna S; Auvergnon N; Noraz N; Rogemond V; Honnorat J; Moradi-Améli M; Giraudon P
    J Biol Chem; 2009 May; 284(19):13265-76. PubMed ID: 19276087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen-glucose deprivation and reoxygenation.
    Li CY; Li X; Liu SF; Qu WS; Wang W; Tian DS
    Neurochem Int; 2015; 83-84():9-18. PubMed ID: 25770080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of AMPK/mTOR/S6K1 pathways and the insulin-sensitizing effect for adiponectin in endometrial cancer cells].
    Cai ZF; Deng L; Wang MM; Zhang JQ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2018 Aug; 53(8):554-560. PubMed ID: 30138966
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1 Signals Influence T Cell Activation Independently of Ribosomal Protein S6 Phosphorylation.
    Salmond RJ; Brownlie RJ; Meyuhas O; Zamoyska R
    J Immunol; 2015 Nov; 195(10):4615-22. PubMed ID: 26453749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast-derived CXCL12/SDF-1α promotes CXCL6 secretion and co-operatively enhances metastatic potential through the PI3K/Akt/mTOR pathway in colon cancer.
    Ma JC; Sun XW; Su H; Chen Q; Guo TK; Li Y; Chen XC; Guo J; Gong ZQ; Zhao XD; Qi JB
    World J Gastroenterol; 2017 Jul; 23(28):5167-5178. PubMed ID: 28811711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
    Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
    Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR Promotes Antiviral Humoral Immunity by Differentially Regulating CD4 Helper T Cell and B Cell Responses.
    Ye L; Lee J; Xu L; Mohammed AU; Li W; Hale JS; Tan WG; Wu T; Davis CW; Ahmed R; Araki K
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27974559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p70 S6K1 nuclear localization depends on its mTOR-mediated phosphorylation at T389, but not on its kinase activity towards S6.
    Rosner M; Schipany K; Hengstschläger M
    Amino Acids; 2012 Jun; 42(6):2251-6. PubMed ID: 21710263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL12 has therapeutic value in facial nerve injury and promotes Schwann cells autophagy and migration via PI3K-AKT-mTOR signal pathway.
    Gao D; Tang T; Zhu J; Tang Y; Sun H; Li S
    Int J Biol Macromol; 2019 Mar; 124():460-468. PubMed ID: 30391592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.
    Cheng KY; Hao M
    Med Sci Monit; 2017 Apr; 23():2017-2028. PubMed ID: 28446743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.